Panel Detail

Sunday, September 9, 2012
11:40 AM - 12:30 PM

Investment Opportunities in Medical Research


Margaret Hamburg, Commissioner, U.S. Food and Drug Administration
Jim Healy, Managing General Partner, Sofinnova
Jonathan Leff, Managing Director, Warburg Pincus
Francois Maisonrouge, Senior Managing Director, Evercore Partners
Dennis Purcell, Senior Managing Partner, Aisling Capital


Mark Simon, Advisor, Torreya Partners
The United States is the world's leading biomedical innovator thanks to a dynamic and highly productive medical research ecosystem that includes universities, government and business. One of the engines of this ecosystem has been private investment from venture capital, private equity and other sources, which has helped build new companies that have brought new treatments and life-saving medicines to patients. In recent years, investment in this sector has slowed, due to decreased risk-taking, regulatory hurdles and other issues. Nonetheless, opportunities remain, particularly for promising, innovative research coming from biotechnology companies. What can be done to revitalize private biomedical investment? Where do opportunities lie in the coming years?

Panel Video

th investmentopps

Click image above to play video